Malignant mixed Müllerian tumor of the ovary

Malignant mixed Müllerian tumor (MMMT) of the ovary, also known as ovarian carcinosarcoma, is an extremely rare and aggressive gynecological malignancy that arises in the ovary. This tumor is classified as a biphasic neoplasm, meaning it contains both malignant epithelial (carcinomatous) and malignant mesenchymal (sarcomatous) components. The carcinomatous element is typically of serous, endometrioid, or undifferentiated type, while the sarcomatous component may be homologous (containing tissue types normally found in the ovary, such as fibrosarcoma) or heterologous (containing tissue types not normally found in the ovary, such as cartilage, bone, or skeletal muscle elements). MMMTs of the ovary primarily affect the female reproductive system but frequently present at advanced stages with widespread peritoneal dissemination, similar to high-grade epithelial ovarian cancers. Patients typically present with symptoms common to ovarian malignancies, including abdominal or pelvic pain, abdominal distension or bloating, a palpable pelvic or abdominal mass, and ascites. Weight loss, fatigue, and gastrointestinal symptoms such as nausea or changes in bowel habits may also occur. The disease predominantly affects postmenopausal women, with a median age at diagnosis typically in the sixth to seventh decade of life. Due to the nonspecific nature of early symptoms, most patients are diagnosed at an advanced stage (FIGO stage III or IV). The current treatment approach mirrors that of high-grade epithelial ovarian cancer and generally involves aggressive cytoreductive (debulking) surgery followed by platinum-based combination chemotherapy, most commonly carboplatin and paclitaxel. Despite treatment, the prognosis remains poor, with overall survival significantly worse than that of high-grade serous ovarian carcinoma. The rarity of this tumor has made it difficult to conduct large-scale clinical trials, and optimal management strategies continue to evolve. Patients are encouraged to seek care at specialized gynecologic oncology centers.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Malignant mixed Müllerian tumor of the ovary